

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**21 CFR Part 524**

**Ophthalmic and Topical Dosage Form New Animal Drugs; Triamcinolone Acetonide Cream**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

---

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Med-Pharmex, Inc. The ANADA provides for veterinary prescription use of triamcinolone acetonide cream on dogs for topical treatment of allergic dermatitis and summer eczema.

**DATES:** This rule is effective *[insert date of publication in the Federal Register]*.

**FOR FURTHER INFORMATION CONTACT:** Lonnie W. Luther, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0209.

**SUPPLEMENTARY INFORMATION:** Med-Pharmex, Inc., 2727 Thompson Creek Rd., Pomona, CA 91767-1861, filed ANADA 200-275 that provides for veterinary prescription use of triamcinolone acetonide cream on dogs for topical treatment of allergic dermatitis and summer eczema. Med-Pharmex's ANADA 200-275 MEDALOG cream is approved as a generic copy of Fort Dodge Animal Health's NADA 46-146 VETALOG® cream. ANADA 200-275 is approved as of February 4, 2000, and 21 CFR 524.2481(b) is amended to reflect the approval. The basis for approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support

DMB

Display Date	3-30-00
Publication Date	3-29-00
Certifier	SNK/ese

461 00 MAR 29 17 55

approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

#### **List of Subjects in 21 CFR Part 524**


Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 524 is amended as follows:

#### **PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS**

1. The authority citation for 21 CFR part 524 continues to read as follows:


**Authority:** 21 U.S.C. 360b.



**§ 524.2481 [Amended]**

2. Section 524.2481 *Triamcinolone acetonide cream* is amended in paragraph (b) by adding after "No." the phrase "051259 and".

Dated: 3/20/00  
March 20, 2000



Stephen F. Sundlof  
Director  
Center for Veterinary Medicine

[FR Doc. 00-???? Filed ??-??-00; 8:45 am]

**BILLING CODE 4160-01-F**

**CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL.**

